Intrauterine contraceptive devices (IUDs) are becoming

Size: px
Start display at page:

Download "Intrauterine contraceptive devices (IUDs) are becoming"

Transcription

1 Malpositioned Intrauterine Contraceptive Devices Risk Factors, Outcomes, and Future Pregnancies Kari P. Braaten, MD, MPH, Carol B. Benson, MD, Rie Maurer, MA, and Alisa B. Goldberg, MD, MPH OBJECTIVE: To assess possible risk factors, management, and outcomes for women with malpositioned intrauterine contraception devices (IUDs). METHODS: This retrospective case control study compared 182 women with malpositioned IUDs shown by ultrasonography at a single institution from 2003 to 2008 with 182 women with properly positioned IUDs. We evaluated whether insertion at 6 9 weeks postpartum, postabortion placement, breastfeeding, type of IUD, pregnancy history, leiomyomas, suspected adenomyosis, and indication for placement were associated with malpositioning. Our study had 70 99% power to detect whether postpartum placement was associated with an odds ratio (OR) of 2 3. RESULTS: Malpositioned devices were noted on 10.4% of ultrasonography scans among women with IUDs having pelvic ultrasonography for any indication. Most malpositioned devices (73.1%) were noted to be in the lower uterine segment or cervix. Insertion of IUDs at 6 9 weeks postpartum was not associated with malpositioning (OR 1.46, 95% confidence interval [CI] ). Among other possible risk factors examined, suspected adenomyosis was associated with IUD malpositioning (OR 3.04, 95% CI ), whereas prior vaginal delivery (OR % CI ) and private insurance (OR 0.38, 95% CI ) were protective. Approximately twothirds (66.5%) of malpositioned devices were removed by health care providers. There were more pregnancies within 2 years among those in the case group than those in the control group (19.2% compared with 10.5%, From the Departments of Obstetrics, Gynecology, and Reproductive Biology and Radiology and the Center for Clinical Investigation, Brigham and Women s Hospital, Boston, Massachusetts. Corresponding author: Kari P. Braaten, MD, MPH, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women s Hospital, One Brigham Circle, 1620 Tremont Street, 3rd Floor, Boston, MA 02120; kpbraaten@partners.org. Financial Disclosure The authors did not report any potential conflicts of interest by The American College of Obstetricians and Gynecologists. Published by Lippincott Williams & Wilkins. ISSN: /11 P.046). All pregnancies were the result of IUD expulsion or removal, and none occurred with a malpositioned IUD known to be in situ. CONCLUSION: Malpositioning of IUDs does not appear to be associated with insertion at 6 9 weeks postpartum. Women with malpositioned IUDs are more likely to become pregnant because of IUD removal without initiation of another highly effective contraceptive method. (Obstet Gynecol 2011;118: ) DOI: /AOG.0b013e LEVEL OF EVIDENCE: II Intrauterine contraceptive devices (IUDs) are becoming increasingly common, and are now the contraceptive method of choice for 5.5% of United States women. 1 With frequent use of pelvic ultrasonography to evaluate gynecologic complaints, the discovery of malpositioned IUDs has also become a more common occurrence. Little is known about factors that predispose to IUD malpositioning or the ideal management of malpositioned devices. Anecdotally, there is concern that IUDs placed in the late postpartum period may be associated with increased rates of malpositioning, although no prior studies have examined this directly. Some studies have shown increased rates of perforation when IUDs are inserted in the postpartum period and in lactating women, 2 4 whereas other studies have not shown significant differences in perforation rates according to postpartum or breastfeeding status. 5,6 With regard to efficacy, studies have shown that copper IUDs have decreased contraceptive efficacy if not located in the fundal portion of the uterus. 7 9 Therefore, copper IUDs noted to be malpositioned should be removed and replaced. The levonorgestrelreleasing intrauterine system has a different mechanism of action, and it seems likely that the local effect of the levonorgestrel is adequate for contraception even if the device is not at the fundus. This hypothesis 1014 VOL. 118, NO. 5, NOVEMBER 2011 OBSTETRICS & GYNECOLOGY

2 is supported by a randomized clinical trial that compared an intracervical device that releases the same dose of levonorgestrel as the levonorgestrel-releasing intrauterine system with the levonorgestrel-releasing intrauterine system placed at the fundus. This study demonstrated no difference in pregnancy rates between the intracervically and the fundally positioned devices. 10 The goal of our study was to estimate if IUD insertion 6 9 weeks postpartum increases the risk of malpositioning. We also sought to identify other possible risk factors for IUD malpositioning and to examine the management and outcomes of women with a malpositioned IUD noted on ultrasonography, including removal and subsequent pregnancy rates. MATERIALS AND METHODS We performed a case control study to estimate the effects of postpartum IUD insertion and other factors on the risk of subsequent IUD malpositioning noted by ultrasonography. We searched the radiology clinical database that includes reports of ultrasound examinations done at Brigham and Women s Hospital from January 1, 2003, to June 30, 2008, using the terms IUD or intrauterine device. Those in the case group were those patients whose ultrasound examinations demonstrated an IUD that was described as being in the lower uterine segment, cervix, rotated, embedded, intraperitoneal, or expelled. The determination of the location of the IUD was made by experienced attending radiologists who interpreted the transvaginal ultrasound examinations. No specific criteria or measurements such as distance from the fundus were used. Control participants were defined as patients with normally positioned IUDs and were selected as the next consecutive patient in the radiology database with a normally located IUD after the given study case. Control participants were chosen in a 1:1 ratio with case participant. Only patients who had a formal ultrasonograph done in the radiology department were included in this study; no ultrasound examinations done in clinics or offices were included. Once participants for the case and control groups were identified, the hospital electronic medical record system was searched using medical record numbers, and the primary investigator abstracted all data onto a standardized coded abstraction form. The electronic medical record system used for our institution includes hospital records for all patients and office records for some physician groups. Paper records were not searched and patient interviews were not conducted. Data were abstracted between January and August 2009 and entered into a secure database created for the purpose of this study. The study was approved by the Partners Healthcare institutional review board. The primary exposure variable was IUD insertion 6 9 weeks postpartum. Other potential exposure variables that were hypothesized to be potential risk factors for IUD malpositioning included immediate postabortal insertion, breastfeeding at the time of insertion, type of IUD (levonorgestrel-releasing intrauterine system or copper IUD), pregnancy history including parity and mode of delivery, presence of uterine leiomyomas or suspected adenomyosis, prior loop electrosurgical excision procedure, and whether the IUD was placed for contraception or the treatment of gynecologic symptoms. Although a definitive diagnosis of adenomyosis requires surgical pathology, adenomyosis is often suspected on clinical or radiologic grounds. Women with a clinical diagnosis of suspected adenomyosis in the electronic medical record or an ultrasonography report that described a possible diagnosis of adenomyosis were defined as having suspected adenomyosis. All radiologic diagnoses of suspected adenomyosis were made by attending radiologists who subspecialize in ultrasonography. The diagnosis was made by transvaginal ultrasonography when a region of the myometrium appeared thickened and heterogeneous, had irregular shadowing, and contained small cysts and interspersed hyperechoic tissue. We also collected data on the indication for the ultrasound examination to examine if there was a relationship between presenting symptoms and malpositioned devices and to control for this factor in the event of confounding. Demographic data including age, ethnicity, marital status, and type of insurance coverage were also collected. We examined what response was taken by providers to the malpositioning. Management outcomes were defined as immediate removal (during the same day or encounter), delayed (removed as a result of malpositioning within 1 year), IUD left in situ, expelled, or unknown. For those women whose IUDs were removed or expelled, we noted whether they were provided with alternative contraception and what type of contraception. Information on pregnancy rates within 2 years for participants in both the study case and control groups was recorded, including whether the pregnancy was planned. For patients whose initial IUD ultrasound examination was done less than 2 years from data collection, pregnancies were recorded up until the time of data collection. The final sample size was a convenience sample of all cases of malpositioned IUDs that were available in the ultrasonography database from January 1, 2003, to June 30, A sample size calculation was VOL. 118, NO. 5, NOVEMBER 2011 Braaten et al Malpositioned Intrauterine Devices 1015

3 performed before the study using the two independent proportion methods. 11 The control group was not matched on any variables, but rather chosen using a 1:1 ratio; therefore, matching was not accounted for in our sample size calculation or analysis. We assumed that the probability of postpartum insertion in the control group was 15% 40%. A sample size of 180 participants in the case group and 180 participants in the control group would allow us to detect an odds ratio (OR) ranging from 2.0 to 3.0 with a two-sided of 0.05 and 70% 99% power. Given these numbers, and the exploratory nature of this study, we were aware of the possibility that we might be underpowered to detect a significant difference for our primary as well as secondary outcomes. Statistical analysis of baseline characteristics and univariable analysis were performed using t tests for numerical variable comparisons and chi-squared or Fisher s exact tests for categorical variable comparisons. Several exposure variables had more than 10% missing data: postpartum insertion (15%), postabortion insertion (14%), breastfeeding (25%), type of IUD (13%), and IUD placed for treatment of gynecologic symptoms (14%). Breastfeeding status was most commonly not available; however, the pattern of missing data appeared completely random. Therefore, we applied the multiple imputation method for analysis of missing data. Exposure variables with a univariable significance of P.10 were selected for logistic regression model building. Both forward and stepwise selection methods were used and those maintaining a P.05 were kept. The univariable predictors not included in the model were manually re-entered for an assessment of confounding effects. Interaction effects among the significant variables were also assessed. Assessment of model fit was tested using Hosmer and Lemeshow chi-squared tests. Odds ratios with 95% confidence intervals (CIs) and two-sided P values were reported for the final model. RESULTS We identified 1,748 pelvic ultrasound reports containing the terms IUD or intrauterine device in the period from January 2003 to June From these, 182 ultrasound examinations revealed malpositioned IUDs, and the women with these ultrasound examinations were our study case group. This represented a rate of malpositioning of 10.4% (95% CI 9% 12%) among IUD users having pelvic ultrasonography for any indication. Baseline demographic factors of those in the study case and control groups are shown in Table 1. There were no differences between those in the study case and control groups by age, parity, or Table 1. Baseline Demographic Characteristics of Those in the Case and Control s Case (n 182) Control (n 182) P* Age (y) Parity (8) 18 (10) 1 or more 158 (87) 158 (87) Unknown 10 (5) 6 (3) Ethnicity.021 White 38 (20.9) 61 (33.5) African American 63 (34.6) 41 (22.5) Hispanic 74 (40.7) 73 (40.1) Other 3 (1.6) 5 (2.8) Unknown 4 (2.2) 2 (1.1) Insurance.001 Medicaid or Medicare 104 (57.1) 68 (37.4) Private 48 (26.4) 73 (40.1) HMO 16 (8.8) 35 (19.2) None or self-pay 12 (6.6) 2 (1.1) Unknown 2 (1.1) 4 (2.2) Marital status.065 Single 92 (50.5) 70 (38.5) Married 81 (44.5) 99 (54.4) Divorced 9 (5.0) 10 (5.5) Widowed 0 (0) 2 (1.1) Unknown 0 (0) 1 (0.5) HMO, health maintenance organization. Data are mean standard deviation or n (%) unless otherwise specified. * P values were generated by excluding missing data. marital status. There were statistically significant differences in race and ethnicity and insurance status between groups. There was a higher proportion of African American and a lower proportion of white patients among those in the case group. Those in the case group also were less likely to have private insurance than were those in the control group. The most common type of malpositioning was the presence of the IUD in the lower uterine segment or cervix, which was found in 133 (73.1%) of the 182 women in the case group. Of these, 29 were also described as being embedded, rotated, or both. There were 21 IUDs that were embedded only or embedded and rotated (11.5%), 13 were expelled (7.1%), and 13 were intraperitoneal (7.1%). Thirty-four IUDs (18.7%) were described as being malpositioned in more than one way. There was no increased risk of IUD malpositioning with insertion 6 9 weeks postpartum (OR 1.46, 95% CI ) or postabortion insertion (OR 0.78, 95% CI ). The only factor which was found to be associated with IUD malpositioning in the univariable analysis was suspected adenomyosis (OR 1016 Braaten et al Malpositioned Intrauterine Devices OBSTETRICS & GYNECOLOGY

4 Table 2. Risk Factors for Intrauterine Device Malpositioning (Univariable Analysis) Case Control Odds Ratio (95% Confidence Interval) P Postpartum insertion (6 9 wk) 45 (24.7) 32 (17.6) 1.46 ( ).204 Post-abortion insertion 3 (1.6) 3 (1.6) 0.78 ( ).793 Breastfeeding at time of insertion 41 (22.5) 36 (19.8) 1.24 ( ).385 Type of IUD 1.06 ( ).795 Copper 83 (45.6) 83 (45.6) Lng-IUS 77 (42.3) 72 (39.6) IUD placed for treatment of 28 (15.4) 28 (15.4) 0.96 ( ).904 gynecological symptoms IUD placed for contraception 148 (81.4) 157 (86.3) 0.62 ( ).232 Known leiomyomas 46 (25.3) 36 (19.8) 1.39 ( ).197 Prior vaginal delivery* 114 (62.7) 130 (71.4) 0.68 ( ).101 History of LEEP 13 (7.1) 14 (7.7) 1.01 ( ).975 Suspected adenomyosis 19 (10.4) 6 (3.3) 3.48 ( ).001 Endometriosis 9 (5.0) 10 (5.5) 1.04 ( ).938 IUD, intrauterine device; Lng-IUS, levonorgestrel-releasing intrauterine system; LEEP, loop electrosurgical excision procedure. Data are n (%) unless otherwise specified. * Prior vaginal delivery includes women with vaginal delivery or vaginal delivery and cesarean delivery compared with women who had no deliveries or cesarean deliveries only. 3.48, 95% CI ), whereas prior vaginal delivery (with or without another delivery by cesarean delivery) was protective (OR 0.68, 95% CI ) (Table 2). There were no differences according to type of IUD, breastfeeding status, indication for IUD placement, known leiomyomas, history of loop electrosurgical excision procedure, or endometriosis. Not surprisingly, we found that more women in the case group had their initial ultrasonography performed for symptoms suggestive of IUD malpositioning, including pain, bleeding, and pregnancy. We also found that having symptoms suggestive of IUD malpositioning was associated with a diagnosis of suspected adenomyosis. Controlling for this confounding relationship in a multivariable model, we found that suspected adenomyosis remained a statistically significant risk factor for malpositioning (OR 3.04, 95% CI ) as did having an ultrasound examination for symptoms suggestive of malpositioning (OR 1.74, 95% CI ). Prior vaginal delivery (OR 0.53, 95% CI ) and private insurance status (OR 0.38, 95% CI ) remained protective (Table 3). The Hosmer-Lemeshow test from the multivariable model did not indicate a lack of model fit (P.61). When taken together, all types of IUD malpositioning did not appear to be associated with postpartum placement or breastfeeding; however, when examining specifically the 13 patients with intraperitoneal (perforated) IUDs, an increased risk was observed with insertion 6 9 weeks postpartum (OR 8.77, 95% CI , P.001) and breastfeeding (OR 11.81, 95% CI , P.008) (data not shown). Among the 182 women with malpositioned IUDs, 121 (66.5%) had their IUDs removed. Fortyone of these women (33.9% of 121) had the device removed immediately and 80 (66.1% of 121) had the device removed between 1 and 250 days after diagnosis of malpositioning. Only 28 (15.4%) IUDs were kept in place once they were discovered to be malpositioned. Of those whose IUDs were removed or expelled, 93 women (77%) planned to initiate an alternative method of birth control, but only 37 (30.6%) received another highly effective form of birth control (another IUD, implant, or sterilization) (Fig. 1). Table 3. Multivariable Logistic Regression Analysis for Intrauterine Device Malpositioning Risk Factors for IUD Malpositioning Multivariate Logistic Regression Odds Ratio (95% Confidence Interval) P Private insurance 0.38 ( ).001 Prior vaginal delivery* 0.53 ( ).013 Suspected adenomyosis 3.04 ( ).035 Indication for ultrasonography: symptom suggestion displacement 1.74 ( ).015 IUD, intrauterine device. * Prior vaginal delivery includes women with vaginal delivery or vaginal delivery and cesarean delivery compared with women who had no deliveries or cesarean deliveries only. VOL. 118, NO. 5, NOVEMBER 2011 Braaten et al Malpositioned Intrauterine Devices 1017

5 30 Women with malpositioned intrauterine device removed (%) None New Oral intrauterine contraceptive device pill Patch Ring Injectable contraceptive Alternative birth control method Barrier method Sterilization Fig. 1. Alternative birth control prescribed to women whose intrauterine contraceptive device was removed as a result of malpositioning. Braaten. Malpositioned Intrauterine Devices. Obstet Gynecol In the 2 years after the index pelvic ultrasound examination, there were more pregnancies among those in the study case group than those in the control group (19.2% compared with 10.5%, P.046) (Table 4). Of the 35 pregnancies that occurred among those in the study case group, 32 (91.4%) were among women whose IUD was known to have ultimately been removed or expelled. Two of the malpositioned IUDs that were ultimately removed were initially left in despite malpositioning and later removed for other reasons, one for pain and one for desired pregnancy. The remaining three pregnancies among those in the study case group were women for whom the outcome of their IUD was unknown. There were no pregnancies that occurred with a malpositioned IUD known to be in situ. Among the 19 control participants with a normally positioned IUD who became pregnant during the follow-up period, 18 had their IUD removed before becoming pregnant and one patient had an ectopic pregnancy with a normally positioned Table 4. Comparison of Future Pregnancies Between Those in the Case and Control s Case (n 182) Control (n 182) P* Pregnancy within 2 y.046 No 124 (68.1) 132 (72.5) Yes 35 (19.2) 19 (10.5) Desired 14 (40.0) 6 (31.6).45 Undesired 14 (40.0) 11 (57.9) Unknown 7 (20.0) 2 (10.5) Pregnancy status unknown 21 (11.6) 31 (17.0) N/A 2 (1.1) 0 (0) * P value was obtained when unknown and N/A combined. N/A includes patients with prior sterilization with intrauterine device in place for treatment of gynecologic symptoms only. copper IUD in place. Despite an overall higher pregnancy rate among those in the study case group than those in the control group, the proportion of unplanned pregnancies was not statistically different between groups (40.0% compared with 57.9%, P.45). DISCUSSION Our study did not demonstrate an association between IUD malpositioning and insertion 6 9 weeks postpartum. We did, however, find that malpositioned IUDs were more likely to be found among women with suspected adenomyosis and less likely to be found among women with a prior vaginal delivery and private insurance. Importantly, we also found a significantly higher rate of subsequent pregnancy among women with malpositioned IUDs, none of which occurred with the malpositioned device in place. It is encouraging that we did not demonstrate an overall increased rate of IUD malpositioning with insertion 6 9 weeks postpartum, because this is an important time for access to effective contraception for many women. However, we did see an elevated risk of intraperitoneal (perforated) IUDs in women who were 6 9 weeks postpartum or breastfeeding, which is consistent with prior findings. 2 4 The absolute number of intraperitoneal IUDs observed was small and the CI was wide for this subgroup analysis. Therefore, we feel that concern for increased risk of perforation should not be a reason to defer IUD insertion during this time period; however, prospective research is needed to accurately estimate the risk of perforation with IUD insertion during the postpartum period and with breastfeeding. The other notable finding of our study is that women with malpositioned IUDs were more likely to become pregnant within the 2 years that followed 1018 Braaten et al Malpositioned Intrauterine Devices OBSTETRICS & GYNECOLOGY

6 their ultrasound examination. Among the women for whom follow-up data were available, pregnancies among women with malpositioned IUDs occurred only when the IUDs were removed; there were no pregnancies seen with a malpositioned IUD in place. In women with normally positioned IUDs, pregnancies also predominantly occurred when IUDs were removed, although there was one ectopic pregnancy with a normally positioned copper IUD in place. The higher pregnancy rate among those in the study case group, therefore, indicates that women with malpositioned IUDs have high discontinuation rates and removed devices are often not immediately replaced with highly effective contraception, resulting in a higher pregnancy rate. Although health care providers may remove malpositioned IUDs due to fear of decreased efficacy, our study demonstrates that the typical use failure rates of other contraceptive methods appear far greater than the theoretical risk of decreased efficacy with a malpositioned IUD. Therefore, patients who are asymptomatic with a malpositioned IUD in the uterus may be best served by either leaving the device in place or removing the device only when it can be immediately replaced with another highly effective method of contraception. Women who have symptoms such as pain or bleeding and who are found to have a malpositioned device may require IUD removal to relieve their symptoms; however, they too would be best served by initiating another highly effective method at the time of IUD removal. Having had one malpositioned IUD removed or expelled is not a contraindication to reinsertion of a new device, and although malpositioning may recur, it is likely that women who were symptomatic from a malpositioned device might not have recurrence of symptoms with a device that is properly placed. The association between malpositioning and suspected adenomyosis was an unexpected finding of our study. Previous studies have found higher rates of expulsion in women with heavy menses for whom the etiology of menorrhagia was unknown and in women with uterine leiomyomas. 12,13 The reason for the association between adenomyosis and IUD malpositioning could be abnormal uterine contractility in women with adenomyosis, which has previously been demonstrated These patients may also have more difficult IUD placements from distortion of the uterine cavity. 17 It is also possible that this finding is the result of unaddressed bias. Although we found that the indication for ultrasonography (ie, referral for ultrasonography for pain or bleeding) confounded the relationship between suspected adenomyosis and malpositioning, when we controlled for this in our multivariable model, the association between suspected adenomyosis and malpositioning remained significant. We acknowledge that given the retrospective nature of this study, there were no predetermined criteria used by the radiologists for the definition of malpositioning or adenomyosis. It seems unlikely that radiologists characterize adenomyosis differently in the presence of a malpositioned IUD; however, it is possible that an IUD was more likely to be interpreted as being located in the lower uterine segment in an enlarged adenomyotic uterus. Interestingly, the same association was not observed for women with leiomyomas. Thus, this finding should be interpreted with caution. Our study must be interpreted in the context of its study design. This was a small retrospective study, which began as exploratory in nature and was limited by the number of cases that were observed during the time period in question. As such, we only had power to detect an OR of 2 3 for our primary outcome and it is possible that there exists an increased risk of a smaller magnitude that we were not able to detect. Our sample size and power calculation were based on examining the relationship between IUD malpositioning and postpartum insertion, and the analysis of secondary outcomes such as pregnancy rate or subgroup analysis were likely underpowered. Despite this, our findings of increased malpositioning with suspected adenomyosis, the protective effect of vaginal delivery, and the increased rate of intraperitoneal IUDs with postpartum insertion or breastfeeding were statistically significant. Other limitations include the possibility of selection bias because we selected control participants from a large pool of possible control participants. However, we do not have any reason to believe that sequential selection of control participants from the ultrasonography database would result in systematic bias that would alter the results of our study. Finally, it is possible that there were pregnancies that were diagnosed and managed outside of our hospital system that we were not able to capture. Indeed, there were 21 individuals in the case group and 31 in the control group for whom there was no available information on future pregnancies in our medical records. However, there is no reason to suspect that the rate of pregnancies managed outside our hospital system would differ between these two groups. Our study also raises questions about the commonly held belief that all malpositioned IUDs should be removed, because we demonstrated that removed devices are often not immediately replaced with highly effective contraceptive methods and removal may result in higher pregnancy rates. Although VOL. 118, NO. 5, NOVEMBER 2011 Braaten et al Malpositioned Intrauterine Devices 1019

7 women who have expelled one device have an increased likelihood of repeat expulsion, the risk of recurrence of IUD malpositioning is unknown. 18 More research is needed to understand the risks and benefits of removal of malpositioned devices and whether removal and reinsertion, possibly under ultrasonographic guidance, offers improved outcomes. REFERENCES 1. Mosher WD, Jones J. Use of contraception in the United States: Vital Health Stat ;29: Caliskan E, Ozturk N, Dilbaz BO, Dilbaz S. Analysis of risk factors associated with uterine perforation by intrauterine devices. Eur J Contracept Reprod Health Care 2003;8: Andersson K, Ryde-Blomqvist E, Lindell K, Odlind V, Milsom I. Perforations with intrauterine devices. Report from a Swedish survey. Contraception 1998;57: Heartwell SF, Schlesselman S. Risk of uterine perforation among users of intrauterine devices. Obstet Gynecol 1983;61: Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: a systematic review. Contraception 2009; 80: Chi I, Potts M, Wilkens LR, Champion MS. Performance of the copper T-380A intrauterine device in breastfeeding women. Contraception 1989;39: Anteby E, Revel A, Ben-Chetrit A, Rosen B, Tadmor O, Yagel S. Intrauterine device failure: relation to its location within the uterine cavity. Obstet Gynecol 1993;81: Bernaschek G, Spernol R, Beck A. The position of the IUD and intrauterine pregnancy [in German]. Geburtshilfe Frauenheilkd 1981;41: Schmidt EH, Wagner H, Quakernack K, Beller FK. Results of the follow-up of the position of intra-uterine device by ultrasonography [in German]. Geburtshilfe Frauenheilkd 1979;39: Pakarinen P, Luukainen T. Five years experience with a small intracervical/intrauterine levonorgestrel-releasing device. Contraception 2005;72: Fleiss JL, Levin B, Pail MC. Statistical methods for rates and proportions. 3rd ed. New York (NY): John Wiley & Sons; Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002;65: Kaunitz AM. Progestin-releasing intrauterine systems and leiomyoma. Contraception 2007;75:S Aguilar HN, Mitchell BF. Physiological pathways and molecular mechanisms regulating uterine contractility. Hum Reprod Update 2010;16: Kissler S, Zangos S, Wiegratz I, Kohl J, Rody A, Gaetje R, et al. Utero-tubal sperm transport and its impairment in endometriosis and adenomyosis. Ann N Y Acad Sci 2007;1101: Mehasseb MK, Bell SC, Pringle JH, Habiba MA. Uterine adenomyosis is associated with ultrastructural features of altered contractility in the inner myometrium. Fertil Steril 2010;93: Peng FS, Wu MY, Yang JH, Chen SU, Ho HN, Yang YS. Insertion of the Mirena intrauterine system for treatment of adenomyosis-associated menorrhagia: a novel method. Taiwan J Obstet Gynecol 2010;49: Bahamondes L, Diaz J, Marchi NM, Petta CA, Cristofoletti ML, Gomez G. Performance of copper intrauterine devices when inserted after an expulsion. Hum Reprod 1995;10: Braaten et al Malpositioned Intrauterine Devices OBSTETRICS & GYNECOLOGY

38 OBG Management August 2012 Vol. 24 No. 8 obgmanagement.com

38 OBG Management August 2012 Vol. 24 No. 8 obgmanagement.com FIGURE 1 Copper intrauterine device displaced in the lower uterine segment with the left arm embedded in the myometrium. illustrations: craig zuckerman for obg management 38 OBG Management August 2012

More information

Zurich Open Repository and Archive

Zurich Open Repository and Archive University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 Partial and complete expulsion of the Multiload 375 IUD and the levonorgestrel-releasing

More information

Product Information. Confidence that lasts

Product Information. Confidence that lasts Confidence that lasts What is Mirena? Inhibition of sperm motility and function inside the uterus and the fallopian tubes, preventing fertilization (Videla-Rivero et al. 1987). Section of system Levonorgestrel

More information

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: Review Article ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com A REVIEW ON INTRAUTERINE DEVICES Boddu Venkata Komali* 1, M. Kalyani

More information

BRIEF REPORTS. Providing Long-Acting Reversible Contraception in an Academic Family Medicine Center Jennifer Amico, MD, MPH; Justine Wu, MD, MPH

BRIEF REPORTS. Providing Long-Acting Reversible Contraception in an Academic Family Medicine Center Jennifer Amico, MD, MPH; Justine Wu, MD, MPH Providing Long-Acting Reversible Contraception in an Academic Family Medicine Center Jennifer Amico, MD, MPH; Justine Wu, MD, MPH BACKGROUND AND OBJECTIVES: Providing long-acting reversible contraception

More information

Instruction for the patient

Instruction for the patient WS 4 Case 3 STI and IUD Your situation Instruction for the patient You are 32 years old, divorced and have one child; you have just started a new relationship You underwent surgical resection of the left

More information

The use of long-acting reversible contraceptive

The use of long-acting reversible contraceptive Overcoming LARC complications: 7 case challenges The strings to your patient s intrauterine device (IUD) are missing. Clinical experience and ACOG direction guide the management plans for this and more

More information

Review of IUCD Complications: Lessons from CAT. Dr FG Mhlanga CAT Meeting 24 September 2016

Review of IUCD Complications: Lessons from CAT. Dr FG Mhlanga CAT Meeting 24 September 2016 Review of IUCD Complications: Lessons from CAT Dr FG Mhlanga CAT Meeting 24 September 2016 INTRODUCTION The intrauterine device (IUD) is a reliable long term reversible, cost-effective,easy to use and

More information

1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.

1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S. 1 2 1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S. The contraceptive action of all IUDs is mainly in the uterine cavity. The major effect

More information

LEARNING OBJECTIVES. Beyond the Pill: Long Acting Contraception. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy is Common

LEARNING OBJECTIVES. Beyond the Pill: Long Acting Contraception. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy is Common 4:15 5 pm Beyond the Pill: Long Acting Contraceptives and IUDs Presenter Disclosure Information The following relationships exist related to this presentation: Christine L. Curry, MD, PhD: No financial

More information

Unintended Pregnancy is Common LEARNING OBJECTIVES. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy And Contraceptive Use

Unintended Pregnancy is Common LEARNING OBJECTIVES. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy And Contraceptive Use 3:45 4:30 pm Beyond the Pill: Long Acting Contraceptives and IUDs Presenter Disclosure Information The following relationships exist related to this presentation: Christine L. Curry, MD, PhD: No financial

More information

Simplifying Vide Contraception. University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok

Simplifying Vide Contraception. University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok Simplifying Vide Contraception University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok Background Objectives At the conclusion of this presentation participants will be able

More information

FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system)

FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system) FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system) Mirena does not protect against HIV infection (AIDS) and other sexually transmitted infections

More information

Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines

Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines 1. Summary statement of the proposal for inclusion LNG-IUS is an effective contraceptive;

More information

What s New in Adolescent Contraception?

What s New in Adolescent Contraception? What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent

More information

Lindsey Tingen, MD Department of Obstetrics and Gynecology, Greenville Health System Greenville, SC

Lindsey Tingen, MD Department of Obstetrics and Gynecology, Greenville Health System Greenville, SC Postpartum IUD Insertion: Continued Usage at Six Months Based on Expulsion and Removal Rates at Greenville Memorial Hospital in the First Year After Adoption of the Practice Lindsey Tingen, MD Department

More information

Gayatrri Anipindi *, Vani I. Original Research Article. Abstract

Gayatrri Anipindi *, Vani I. Original Research Article. Abstract Original Research Article Role of levonorgestrel releasing intrauterine device in management of heavy menstrual bleeding: A safe and effective option for all PALM COEIN variants Gayatrri Anipindi *, Vani

More information

2

2 1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive

More information

Levosert levonorgestrel 20mcg/24hour intrauterine device

Levosert levonorgestrel 20mcg/24hour intrauterine device Levosert levonorgestrel 20mcg/24hour intrauterine device Verdict: Formulary inclusion: Formulary category: Restrictions: Reason for inclusion: Link to formulary: Link to medicine review summary: Levosert

More information

Postpartum LARC. (Long Acting Reversible Contraception) NURSING EDUCATION

Postpartum LARC. (Long Acting Reversible Contraception) NURSING EDUCATION Postpartum LARC (Long Acting Reversible Contraception) NURSING EDUCATION What is LARC Long-acting reversible contraception (LARC) methods include the intrauterine device (IUD) and the birth control implant.

More information

Immediate Postpartum Long-Term Reversible Contraception (LARC) Bethany Berry, CNM, MSN and Alyssa Givens, MSN, RN

Immediate Postpartum Long-Term Reversible Contraception (LARC) Bethany Berry, CNM, MSN and Alyssa Givens, MSN, RN Immediate Postpartum Long-Term Reversible Contraception (LARC) Bethany Berry, CNM, MSN and Alyssa Givens, MSN, RN Disclosures O Bethany Berry CNM is a Nexplanon trainer with Merck O Alyssa Givens, RN has

More information

The most commonly chosen methods of contraception

The most commonly chosen methods of contraception Original Research Effects of Age, Parity, and Device Type on Complications and Discontinuation of Intrauterine Devices Joelle Aoun, MD, Virginia A. Dines, BS, Dale W. Stovall, MD, Mihriye Mete, PhD, Casey

More information

Example CLINICAL GUIDELINES for Postpartum IUD insertion

Example CLINICAL GUIDELINES for Postpartum IUD insertion Example CLINICAL GUIDELINES for Postpartum IUD insertion Postpartum Intrauterine Device Insertion 1.0 Indications: 1.1 Insertion of an intrauterine device (IUD) for long-acting reversible contraception

More information

1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7:

1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7: 1 2 1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7: 777 85. 3 1. Wu JP et al. Extended use of the intrauterine device: a

More information

CODING GUIDELINES FOR CONTRACEPTIVES. Effective June 1, 2017 Version 1.40

CODING GUIDELINES FOR CONTRACEPTIVES. Effective June 1, 2017 Version 1.40 CODING GUIDELINES FOR CONTRACEPTIVES Effective June 1, 2017 Version 1.40 TABLE OF CONTENTS ICD-10 CM Diagnosis Codes: Encounter for Contraception page 2 Coding for IUD Insertion and Removal Procedures

More information

ACCESS LARC INCREASING ACCESS TO IMMEDIATE POSTPARTUM LONG-ACTING REVERSIBLE CONTRACEPTION

ACCESS LARC INCREASING ACCESS TO IMMEDIATE POSTPARTUM LONG-ACTING REVERSIBLE CONTRACEPTION ACCESS LARC INCREASING ACCESS TO IMMEDIATE POSTPARTUM LONG-ACTING REVERSIBLE CONTRACEPTION Chapter Four: Policies and Procedures Overview This procedure outline is a pre-cursor to detailed procedures related

More information

LARC: Disclosures. Long Acting Reversible Contraception. Objectives 10/23/2013. I have no relevant financial disclosures

LARC: Disclosures. Long Acting Reversible Contraception. Objectives 10/23/2013. I have no relevant financial disclosures LARC: Long Acting Reversible Contraception Disclosures I have no relevant financial disclosures Jennifer Kerns, MD, MPH Assistant Professor, UCSF Obstetrics, Gynecology and Reproductive Sciences San Francisco

More information

Long Acting Reversible Contraception: First Line Care for Adolescents. David A. Levine, MD, FAAP Melissa Kottke, MD, MPH, FACOG

Long Acting Reversible Contraception: First Line Care for Adolescents. David A. Levine, MD, FAAP Melissa Kottke, MD, MPH, FACOG Long Acting Reversible Contraception: First Line Care for Adolescents David A. Levine, MD, FAAP Melissa Kottke, MD, MPH, FACOG Disclosures Melissa Kottke is a Nexplanon trainer for Merck Objectives Describe

More information

Example Clinical Guideline for Immediate Postpartum LARC Insertion

Example Clinical Guideline for Immediate Postpartum LARC Insertion Example Clinical Guideline for Immediate Postpartum LARC Insertion RATIONALE Delay in contraceptive provision until the six week postpartum appointment can leave some women at risk for rapid repeat pregnancy.

More information

MEDICAL POLICY SUBJECT: FEMALE STERILIZATION. POLICY NUMBER: CATEGORY: Contract Clarification

MEDICAL POLICY SUBJECT: FEMALE STERILIZATION. POLICY NUMBER: CATEGORY: Contract Clarification MEDICAL POLICY SUBJECT: FEMALE STERILIZATION PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information

LONG-ACTING REVERSIBLE CONTRACEPTION. Summary Tables

LONG-ACTING REVERSIBLE CONTRACEPTION. Summary Tables LONG-ACTING REVERSIBLE CONTRACEPTION Summary Tables Bridging the Divide: A Project of the Jacobs Institute of Women s Health June 2016 Table 1. Summary of LARC Methods Available Years Since Effective Copper

More information

Contraception and gynecological pathologies

Contraception and gynecological pathologies 1 Contraception and gynecological pathologies 18 years old, 2 CMI normal First menstruation at 14 years old Irregular (every 2/3 months), painful + She does not need contraception She is worried about

More information

Differences in Women Who Choose Subdermal Implants Versus Intrauterine Devices

Differences in Women Who Choose Subdermal Implants Versus Intrauterine Devices The Journal of Reproductive Medicine Differences in Women Who Choose Subdermal Implants Versus Intrauterine Devices Vien C. Lam, M.D., Emily E. Hadley, M.D., Abbey B. Berenson, M.D., Ph.D., Jacqueline

More information

An Overview of Long Acting Reversible Contraception Methods

An Overview of Long Acting Reversible Contraception Methods An Overview of Long Acting Reversible Contraception Methods Unintended Pregnancy All pregnancies should be intended; that is, they should be consciously and clearly desired at the time of conception. -

More information

1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7:

1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7: 1 2 1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7: 777 85. 3 1. Wu JP et al. Extended use of the intrauterine device: a

More information

Medical Eligibility for Contraception Use

Medical Eligibility for Contraception Use Medical Eligibility for Contraception Use DIVISION OF REPRODUCTIVE HEALTH CENTERS FOR DISEASE CONTROL AND PREVENTION 2016 US Medical Eligibility Criteria for Contraceptive Use (US MEC) Purpose To assist

More information

Family Planning UNMET NEED. The Nurse Mildred Radio Talk Shows

Family Planning UNMET NEED. The Nurse Mildred Radio Talk Shows Family Planning UNMET NEED The Nurse Mildred Radio Talk Shows TOPIC 9: IUD/COIL Guests FP counsellor from MSU, RHU& UHMG Nurse Mildred Nurse Betty Objectives of the programme: To inform listeners about

More information

Contraception Choices: An Evidence Based Approach Case Study Approach. Susan Hellier PhD, DNP, FNP-BC, CNE

Contraception Choices: An Evidence Based Approach Case Study Approach. Susan Hellier PhD, DNP, FNP-BC, CNE Contraception Choices: An Evidence Based Approach Case Study Approach Susan Hellier PhD, DNP, FNP-BC, CNE Objectives Describe the U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 (U.S. MEC)

More information

International Federation of Gynecology and Obstetrics

International Federation of Gynecology and Obstetrics International Federation of Gynecology and Obstetrics THE ROLE OF POST- ABORTION CONTRACEPTION IN PREVENTION OF UNSAFE ABORTION THE ROLE OF POST- ABORTION CONTRACEPTION IN PREVENTION OF UNSAFE ABORTION

More information

Welcome to Mirena. The Mirena Handbook: A Personal Guide to Your New Mirena. mirena.com. Mirena is the #1 prescribed IUD * in the U.S.

Welcome to Mirena. The Mirena Handbook: A Personal Guide to Your New Mirena. mirena.com. Mirena is the #1 prescribed IUD * in the U.S. Mirena is the #1 prescribed IUD * in the U.S. Welcome to Mirena The Mirena Handbook: A Personal Guide to Your New Mirena *Intrauterine Device Supported by 2015-2016 SHS data INDICATIONS FOR MIRENA Mirena

More information

VCHIP LARC Needs Assessment Survey

VCHIP LARC Needs Assessment Survey VCHIP LARC Needs Assessment Survey Demographics 1. How many have you been in practice (post-training)? Choose one of the following answers 0-5 6-10 11-15 16-20 21 or more 2. What are your professional

More information

Wendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa

Wendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa Wendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa Objectives Distinguish the different types of IUDs Understand the mechanism of action and selection of candidates

More information

levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer

levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer 6 March 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises

More information

Contraceptive Updates and Recommendations

Contraceptive Updates and Recommendations Contraceptive Updates and Recommendations Emily M. Godfrey, MD MPH Associate Professor, Departments of Family Medicine and Obstetrics and Gynecology, University of Washington, Seattle WA Guest Researcher,

More information

Contraceptive Updates and Recommendations

Contraceptive Updates and Recommendations Contraceptive Updates and Recommendations Emily M. Godfrey, MD MPH Associate Professor, Departments of Family Medicine and Obstetrics and Gynecology, University of Washington, Seattle WA Guest Researcher,

More information

Infertility services reported by men in the United States: national survey data

Infertility services reported by men in the United States: national survey data MALE FACTOR Infertility services reported by men in the United States: national survey data John E. Anderson, Ph.D., Sherry L. Farr, Ph.D., M.S.P.H., Denise J. Jamieson, M.D., M.P.H., Lee Warner, Ph.D.,

More information

Maximizing LARC Availability: Bringing the Lessons of the CHOICE Project to Your Community

Maximizing LARC Availability: Bringing the Lessons of the CHOICE Project to Your Community Maximizing LARC Availability: Bringing the Lessons of the CHOICE Project to Your Community Reproductive Health 2012 September 21, 2012 David Turok, MD/MPH Objectives Communicate to colleagues the reduction

More information

Risk factors for IUD failure: results of a large multicentre case control study

Risk factors for IUD failure: results of a large multicentre case control study Human Reproduction Vol.21, No.10 pp. 2612 2616, 2006 Advance Access publication June 14, 2006. doi:10.1093/humrep/del208 Risk factors for IUD failure: results of a large multicentre case control study

More information

Intrauterine Devices (IUDs): Access for Women in the U.S.

Intrauterine Devices (IUDs): Access for Women in the U.S. November 2016 Fact Sheet Intrauterine Devices (IUDs): Access for Women in the U.S. Intrauterine devices (IUDs) are one of the most effective forms of reversible contraception. IUDs, along with implants,

More information

Road to Access: Successes and Challenges in implementation of IPP LARC. Eve Espey, MD MPH New Mexico Perinatal Collaborative ILPQC

Road to Access: Successes and Challenges in implementation of IPP LARC. Eve Espey, MD MPH New Mexico Perinatal Collaborative ILPQC Road to Access: Successes and Challenges in implementation of IPP LARC Eve Espey, MD MPH New Mexico Perinatal Collaborative ILPQC 11-5-18 OR. If at first you don t succeed, try try again Disclosures and

More information

Prescriber Guide for the Letairis REMS Program

Prescriber Guide for the Letairis REMS Program LETAIRIS RISK EVALUATION AND MITIGATION STRATEGY (REMS) Prescriber Guide for the Letairis REMS Program Changes to the Letairis Risk Evaluation and Mitigation Strategy (REMS) Program (November 2018) Revised:

More information

Contraception for Adolescents: What s New?

Contraception for Adolescents: What s New? Contraception for Adolescents: What s New? US Medical Eligibility Criteria for Contraceptive Use Kathryn M. Curtis, PhD Division of Reproductive Health, CDC Expanding Our Experience and Expertise: Implementing

More information

Disclosures. Learning Objectives 4/18/2017 ADOLESCENT CONTRACEPTION UPDATE APRIL 28, Nexplanon trainer for Merck

Disclosures. Learning Objectives 4/18/2017 ADOLESCENT CONTRACEPTION UPDATE APRIL 28, Nexplanon trainer for Merck ADOLESCENT CONTRACEPTION UPDATE APRIL 28, 2017 Brandy Mitchell, MN, RN, ANP BC, WHNP BC University of Iowa Hospitals and Clinics Obstetrics and Gynecology Iowa Association of Nurse Practitioners Spring

More information

Racial and Ethnic Disparities in Contraceptive Method Choice in California

Racial and Ethnic Disparities in Contraceptive Method Choice in California Racial and Ethnic Disparities in Contraceptive Method Choice in California CONTEXT: Unintended pregnancy, an important public health issue, disproportionately affects minority populations. Yet, the independent

More information

Information for Informed Consent for Insertion of a Mirena IUD

Information for Informed Consent for Insertion of a Mirena IUD Information for Informed Consent for Insertion of a Mirena IUD What is an IUD (intrauterine Device)? An intrauterine device (IUD) is a plastic device that is placed into your uterus to prevent pregnancy.

More information

Coding for the Contraceptive Implant and IUDs

Coding for the Contraceptive Implant and IUDs LARC Quick Coding Guide 2018 UPDATE Coding for the Contraceptive Implant and IUDs CORRECT CODING can result in more appropriate compensation for services and devices. To help practices receive appropriate

More information

Extended use of intrauterine devices: How long can we go?

Extended use of intrauterine devices: How long can we go? Extended use of intrauterine devices: How long can we go? Justine P. Wu, MD, MPH Sarah Pickle, MD Rutgers Robert Wood Johnson Medical School Department of Family Medicine & Community Health Disclosures

More information

Patient or Clinician: Duration of Use of Intrauterine Devices Based on Who Initiated Discussion of Placement

Patient or Clinician: Duration of Use of Intrauterine Devices Based on Who Initiated Discussion of Placement ORIGINAL RESEARCH Patient or Clinician: Duration of Use of Intrauterine Devices Based on Who Initiated Discussion of Placement Tammy Chang, MD, MPH, MS, Michelle H. Moniz, MD, MSc, Melissa A. Plegue, MA,

More information

ESSURE A RESOURCE FOR CODING

ESSURE A RESOURCE FOR CODING ESSURE REIMBURSEMENT GUIDE A RESOURCE FOR CODING INDICATION Essure is indicated for women who desire permanent birth control (female sterilization) by bilateral occlusion of fallopian tubes. IMPORTANT

More information

The modern intrauterine device (IUD) is highly reliable and

The modern intrauterine device (IUD) is highly reliable and Intrauterine Device Knowledge and Practices: A National Survey of Obstetrics and Gynecology Residents Jennifer Tang, MD, MSCR, Rie Maurer, MA, and Deborah Bartz, MD, MPH Objectives: The primary objective

More information

the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to

the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to your guide to Helping you choose the method of contraception that s best for you IUD IUD the e IUD IU IUD the IUD 2 3 The intrauterine device (IUD) An IUD is a small plastic and copper device that s put

More information

Examining Long-Acting Reversible Contraceptive Methods

Examining Long-Acting Reversible Contraceptive Methods Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/examining-long-acting-reversible-contraceptivemethods/7078/

More information

Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization

Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization Draft Guidance for Industry and Food and Drug

More information

The number of women using long-acting reversible

The number of women using long-acting reversible Long-acting reversible contraception: Who, what, when, and how This review provides practical tips and dispels some common misconceptions about these devices, which have higher rates of patient satisfaction

More information

Contraception: Common Problems Faced in Office Practice. Jane S. Sillman, MD Brigham and Women s Hospital

Contraception: Common Problems Faced in Office Practice. Jane S. Sillman, MD Brigham and Women s Hospital Contraception: Common Problems Faced in Office Practice Jane S. Sillman, MD Brigham and Women s Hospital Disclosures I have no conflicts of interest Contraception: Common Problems How to discuss contraception

More information

A Study of Physician Recommendations for Reversible Contraceptive Methods Using Standardized Patients

A Study of Physician Recommendations for Reversible Contraceptive Methods Using Standardized Patients A Study of Physician Recommendations for Reversible Contraceptive Methods Using Standardized Patients By Christine Dehlendorf, Kevin Grumbach, Eric Vittinghoff, Rachel Ruskin and Jody Steinauer Christine

More information

PALM-COEIN: Your AUB Counseling Guide

PALM-COEIN: Your AUB Counseling Guide PALM-COEIN: Your AUB Counseling Guide 10 million+ Treat the cause, not the symptom In the U.S, more than 10 million women between the ages of 35 and 49 are affected by AUB 1 Diagnosis Cause Structural

More information

Contraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014

Contraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014 Contraception Tami Allen, RNC OB, MHA Robin Petersen, RN, MSN Perinatal Clinical Nurse Specialist Objectives Discuss the impact of unintended pregnancy in the United States Discuss the risks and benefits

More information

NIH Public Access Author Manuscript Contraception. Author manuscript; available in PMC 2012 November 1.

NIH Public Access Author Manuscript Contraception. Author manuscript; available in PMC 2012 November 1. NIH Public Access Author Manuscript Published in final edited form as: Contraception. 2011 November ; 84(5): 499 504. doi:10.1016/j.contraception.2011.01.022. Postplacental or delayed levonorgestrel intrauterine

More information

2/24/19. Myometrial evaluation. Size Echotexture. Homogeneous Heterogeneous. Adenomyosis Fibroids. Adenomyosis. MUSA guidelines

2/24/19. Myometrial evaluation. Size Echotexture. Homogeneous Heterogeneous. Adenomyosis Fibroids. Adenomyosis. MUSA guidelines Content Adenomyosis and MUSA guidelines for myometrial disorders Adenomyosis MUSA guidelines Dr Lufee Wong FRANZCOG, MPH, DDU Recommended reporting guidelines Fibroids Adenomyosis Myometrial evaluation

More information

Essure By Mayo Clinic staff

Essure By Mayo Clinic staff Page 1 of 5 Reprints A single copy of this article may be reprinted for personal, noncommercial use only. Essure By Mayo Clinic staff Original Article: http://www.mayoclinic.com/health/essure/my00999 Definition

More information

FACTORS ASSOCIATED WITH CHOICE OF POST-ABORTION CONTRACEPTIVE IN ADDIS ABABA, ETHIOPIA. University of California, Berkeley, USA

FACTORS ASSOCIATED WITH CHOICE OF POST-ABORTION CONTRACEPTIVE IN ADDIS ABABA, ETHIOPIA. University of California, Berkeley, USA FACTORS ASSOCIATED WITH CHOICE OF POST-ABORTION CONTRACEPTIVE IN ADDIS ABABA, ETHIOPIA Ndola Prata 1, Caitlin Gerdts 1, Martine Holston, Yilma Melkamu 1 Bixby Center for Population, Health, and Sustainability;

More information

Temporal Trends - Original

Temporal Trends - Original Temporal Trends - Original 1 1 2 Temporal trends in the uptake and continuation of the etonogestrel implant in a large private practice setting. 3 4 David L Howard MD PhD 5 Las Vegas Minimally Invasive

More information

A Comparative Study between the Side Effects of Copper Intrauterine Device in Women with Non-scarred and Scarred Uterus

A Comparative Study between the Side Effects of Copper Intrauterine Device in Women with Non-scarred and Scarred Uterus Iraqi JMS Published by Al-Nahrain College of Medicine ISSN 161-659 Email: Iraqi_jms_alnahrain@yahoo.com http://www. colmed-nahrain.edu.iq/ A Comparative Study between the Side Effects of Copper Intrauterine

More information

Emergency Contraception THE FACTS

Emergency Contraception THE FACTS Emergency Contraception Quick Facts What is it? Emergency contraception is birth control that you use after you have had unprotected sex--if you didn t use birth control or your regular birth control failed.

More information

Long-Acting Reversible Contraception: The Contraceptive CHOICE Project

Long-Acting Reversible Contraception: The Contraceptive CHOICE Project Long-Acting Reversible Contraception: The Contraceptive CHOICE Project Jeffrey F. Peipert, M.D., Ph.D. Vice Chair of Clinical Research Robert J. Terry Professor Department of Obstetrics & Gynecology Washington

More information

Management of Emergency Contraception (EC)

Management of Emergency Contraception (EC) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Management of Emergency Contraception (EC) The risks and benefits of an IUD or oral EC should be discussed and documented (see appendix). Reasonable measures

More information

Key words: Contraception, Copper T380A, Discontinuation.

Key words: Contraception, Copper T380A, Discontinuation. Discontinuation Rates among Women Using either the Combined Oral Contraceptive Pills or an Intrauterine Contraceptive Device for Contraception: A Comparative Study Ehab Al-Rayyan MD*, Zakarya Bani Meri

More information

LARC Quick Coding Guide Supplement

LARC Quick Coding Guide Supplement LARC ICD-10 Coding Reference Basic Implant Codes ICD-10 Codes Implant CPT Procedure Codes HCPCSII/JCode Z30.017 Encounter for initial prescription of other contraceptives (includes 11981 - insertion J7307

More information

Non-contraceptive Uses of the Levonorgestrel Intrauterine Device Elena Gates, MD http://www.mirena-us.com/pvs1/pri/whatisframe.html Progestin levels with LNG- IUS Lower plasma levels Mirena 150-200 pg/ml

More information

Improving the Results Obtained with Current Intrauterine Contraceptive Devices

Improving the Results Obtained with Current Intrauterine Contraceptive Devices Improving the Results Obtained with Current Intrauterine Contraceptive Devices MICHAEL S. BURNHILL, M.D., and CHARLES H. BIRNBERG, M.D. CAREFUL EXAMINATION of many of the clinical studies on the use of

More information

2

2 1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive

More information

A Population-Based Study of Pregnancy and Delivery Characteristics Among Women with Vulvodynia

A Population-Based Study of Pregnancy and Delivery Characteristics Among Women with Vulvodynia Pain Ther (2012) 1:2 DOI 10.1007/s40122-012-0002-7 ORIGINAL RESEARCH A Population-Based Study of Pregnancy and Delivery Characteristics Among Women with Vulvodynia Ruby H. N. Nguyen Elizabeth G. Stewart

More information

Reconsidering racial/ethnic differences in sterilization in the United States

Reconsidering racial/ethnic differences in sterilization in the United States Reconsidering racial/ethnic differences in sterilization in the United States Kari White and Joseph E. Potter Abstract Cross-sectional analyses of women s current contraceptive use demonstrate that low-income

More information

Birth Control- an Overview. Keith Merritt, MD. Remember, all methods of birth control are safer and have fewer side effects than pregnancy

Birth Control- an Overview. Keith Merritt, MD. Remember, all methods of birth control are safer and have fewer side effects than pregnancy Birth Control- an Overview Keith Merritt, MD Basics Remember, all methods of birth control are safer and have fewer side effects than pregnancy Even with perfect use, each method of birth control has a

More information

LARC IN THE OFFICE BASE SETTING. Regina Lewis, DO Associate Professor of Family Medicine OSU Family Medicine

LARC IN THE OFFICE BASE SETTING. Regina Lewis, DO Associate Professor of Family Medicine OSU Family Medicine SHIFT HAPPENS! LARC IN THE OFFICE BASE SETTING Regina Lewis, DO Associate Professor of Family Medicine OSU Family Medicine 1. the effects of teen and unplanned pregnancies 2. types of LARC products 3.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

U.S. Medical Eligibility Criteria for Contraceptive Use, 2010

U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 Division of Reproductive Health Centers for Disease Control and Prevention August 1, 2013 National Center for Chronic Disease Prevention and

More information

SURGICAL PROBLEMS IN FERTILITY- FIBROIDS. Dr.Māris Arājs gyn-ob specialist Cell phone:

SURGICAL PROBLEMS IN FERTILITY- FIBROIDS. Dr.Māris Arājs gyn-ob specialist Cell phone: SURGICAL PROBLEMS IN FERTILITY- FIBROIDS Dr.Māris Arājs gyn-ob specialist maris@myclinicriga.lv Cell phone: +371 26556466 There is NO Industry Sponsorship and Financial Conflict of Interest for this presentation

More information

Disturbance of uterine bleeding patterns, often anecdotally

Disturbance of uterine bleeding patterns, often anecdotally Management of Initial Bleeding or Spotting After Levonorgestrel-Releasing Intrauterine System Placement A Randomized Controlled Trial Terje Sørdal, MD, Pirjo Inki, MD, PhD, John Draeby, MD, Mary O Flynn,

More information

Indian Journal of Basic and Applied Medical Research; September 2015: Vol.-4, Issue- 4, P

Indian Journal of Basic and Applied Medical Research; September 2015: Vol.-4, Issue- 4, P Original article: To study post intrauterine insemination conception rate among infertile women with polyp and women with normal uterine endometrium cavity 1Dr. Archana Meena, 2 Dr. Renu Meena, 3 Dr. Kusum

More information

Chapter 100 Gynecologic Disorders

Chapter 100 Gynecologic Disorders Chapter 100 Gynecologic Disorders Episode Overview: 1. Describe the presentation and RF for Adnexal torsion 2. List the imaging findings of adnexal torsion (US vs CT) 3. What is the management of adnexal

More information

Research. Reported weight gain is one of the

Research. Reported weight gain is one of the Research www.ajog.org GENERAL GYNECOLOGY Validity of perceived weight gain in women using long-acting reversible contraception and depot medroxyprogesterone acetate Ashley M. Nault, BS; Jeffrey F. Peipert,

More information

The Doctor Is In. Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH

The Doctor Is In. Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH The Doctor Is In Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH Contraception Resources from the CDC: 2016 U.S. Medical Eligibility Criteria

More information

CLINICAL GUIDELINES ID TAG Female Sterilisation (tubal occlusion) at Caesarean Section- Guideline for counselling and consent

CLINICAL GUIDELINES ID TAG Female Sterilisation (tubal occlusion) at Caesarean Section- Guideline for counselling and consent Title: Author: Designation: Speciality / Division: Directorate: CLINICAL GUIDELINES ID TAG Female Sterilisation (tubal occlusion) at Caesarean Section- Guideline for counselling and consent Dr Meeta Kamath

More information

Unintended Pregnancy in U.S. The Importance of LARC: What have We Learned? Long-acting Reversible Contraception (LARC)

Unintended Pregnancy in U.S. The Importance of LARC: What have We Learned? Long-acting Reversible Contraception (LARC) Unintended Pregnancy in U.S. The Importance of LARC: What have We Learned? Colleen McNicholas, DO, MSCI Department of Obstetrics & Gynecology Washington University in St. Louis School of Medicine Over

More information

Regret after decision to have a tubal sterilization

Regret after decision to have a tubal sterilization FERTILITY AND STERILITY Copyright c 1985 The American Fertility Society Vol. 44, No.2, August 1985 Printed in U.SA. Regret after decision to have a tubal sterilization Gary S. Grubb, M.D., M.P.H.*t Herbert

More information

RESOLUTION NO. 301 (Co-Sponsored G) SUBSTITUTE ADOPTED See Below

RESOLUTION NO. 301 (Co-Sponsored G) SUBSTITUTE ADOPTED See Below RESOLUTION NO. 301 (Co-Sponsored G) SUBSTITUTE ADOPTED See Below Support Placement and Coverage of Long-Acting Reversible Contraceptives (LARC) in the Early Postpartum Period Introduced by the California

More information

Postpartum intrauterine device placement: a patient-friendly option

Postpartum intrauterine device placement: a patient-friendly option Cwiak and Cordes Contraception and Reproductive Medicine (2018) 3:3 https://doi.org/10.1186/s40834-018-0057-x Contraception and Reproductive Medicine REVIEW Postpartum intrauterine device placement: a

More information